Cocrystal terminates license agreements with Kansas State due to futility; retains CDI-988

Cocrystal Pharma, Inc.

On Feb 28, 2024, Cocrystal notified Kansas State University Research Foundation of termination of two License Agreements (Feb 12, 2020 and Apr 19, 2020), effective March 29, 2024.
Termination due to determination that further development under the Agreements would be futile.
Wholly owned compound CDI-988 (pan-viral for coronavirus and norovirus) is not affected and is in Phase 1 clinical trial.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Cocrystal Pharma, Inc. terminated License Agreements with Kansas State University Research Foundation valued at Early termination of License Agreements dated February 12, 2020 and April 19, 2020 (effective 2024-03-29).

Action: termination
Agreement: license
Counterparty: Kansas State University Research Foundation
Value: Early termination of License Agreements dated February 12, 2020 and April 19, 2020
Effective: 2024-03-29

Exact text from the filing

provided notice to Kansas State University Research Foundation of the Company’s election to terminate the License Agreements (the “Agreements”) dated February 12, 2020 and April 19, 2020. The terminations, which were made due to the Company’s determination that further development efforts under the Agreements would be futile, are effective on March 29, 2024.

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-008493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.